Jeffrey Lawson
Founder at InnAVasc Medical, Inc.
Jeffrey Lawson active positions
| Companies | Position | Start | End |
|---|---|---|---|
Humacyte Global, Inc.
 Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Director/Board Member | 30/06/2018 | - |
| Corporate Officer/Principal | 19/11/2020 | - | |
| Chief Executive Officer | 31/05/2018 | 19/11/2020 | |
| Chief Tech/Sci/R&D Officer | 31/12/2014 | - | |
| President | 31/12/2017 | 19/11/2020 | |
InnAVasc Medical, Inc.
 InnAVasc Medical, Inc. Medical SpecialtiesHealth Technology InnAVasc Medical, Inc. designs and develops products for vascular access for hemodialysis. Its technology vascular access graft is designed to create one contiguous flow lumen without transition points. The company is headquartered in Durham, NC. | Director/Board Member | 12/05/2013 | - |
| Founder | 12/05/2013 | - | |
| Kidney Health Initiative | Director/Board Member | - | - |
| Vascular Access Society of The Americas | Director/Board Member | - | - |
| Foundation For Women & Girls With Blood Disorders | Director/Board Member | - | - |
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Chief Executive Officer | 11/10/2023 | - |
Career history of Jeffrey Lawson
Former positions of Jeffrey Lawson
| Companies | Position | Start | End |
|---|---|---|---|
| HUMACYTE, INC. | Director/Board Member | 25/08/2021 | 30/12/2021 |
| Corporate Officer/Principal | 25/08/2021 | 30/12/2021 |
Training of Jeffrey Lawson
| University of Vermont College of Medicine | Doctorate Degree |
Statistics
International
| United States | 8 |
| Netherlands | 2 |
Operational
| Director/Board Member | 6 |
| Chief Executive Officer | 2 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| HUMACYTE, INC. | Health Technology |
| Private companies | 6 |
|---|---|
Humacyte Global, Inc.
Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Health Technology |
InnAVasc Medical, Inc.
InnAVasc Medical, Inc. Medical SpecialtiesHealth Technology InnAVasc Medical, Inc. designs and develops products for vascular access for hemodialysis. Its technology vascular access graft is designed to create one contiguous flow lumen without transition points. The company is headquartered in Durham, NC. | Health Technology |
| Kidney Health Initiative | |
| Vascular Access Society of The Americas | |
| Foundation For Women & Girls With Blood Disorders | |
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Health Technology |
- Stock Market
- Insiders
- Jeffrey Lawson
- Experience
